When monkeypox cases started climbing outside their usual range in 2022, the bottleneck was not treatment. It was knowing who had the virus. The standard test, a lab PCR run, is accurate but it wants a real machine, trained hands, and a cold chain to move samples to a central lab. In a rural clinic or a crowded field station, that chain breaks. A team at the Second Hospital of Nanjing decided to build something that could survive those conditions, and the result reads out on a strip of paper you hold up to the light.
Their assay pairs two tricks that have been quietly reshaping diagnostics. The first is a room-temperature way to copy the virus's genetic material without the heating and cooling cycles PCR depends on. The second is CRISPR, better known as a gene-editing tool, working here as a molecular bloodhound. The full method is described in a paper published in June in Infectious Diseases of Poverty.
How a gene editor becomes a detector
Most people meet CRISPR as a way to cut and rewrite DNA. This test uses a different member of the family, called Cas13a, which hunts RNA instead. Give Cas13a a short guide sequence that matches the monkeypox virus, and it stays quiet until it finds that exact target. Once it does, it flips into a shredding mode and starts chopping up nearby reporter molecules the researchers planted in the tube. Those reporters are rigged so that cutting them releases a signal.
Here that signal ends up on a lateral flow strip, the same basic format as a home COVID or pregnancy test. A line appears, or it doesn't. Before the CRISPR step, a technique called multienzyme isothermal rapid amplification, or MIRA, multiplies whatever viral material is present at a single warm temperature. No thermal cycler needed. The whole run takes about 40 minutes and can be read by eye.
What the numbers actually showed
The team pushed the test down to very low amounts of virus. Diluting a reference sample step by step, they could still catch it at 14.4 copies per milliliter, a sensitivity that puts it in serious diagnostic territory. Then came the harder test: real patients. They ran 202 clinical monkeypox samples and 104 samples meant to trip the system up, including material from three other poxvirus relatives. The assay called every one correctly. That is 100 percent sensitivity and 100 percent specificity against the clinical panel.
More striking, it disagreed with PCR three times, and in a useful direction. Three samples the test flagged as positive had come back negative on quantitative PCR. Read together with the strip results, those look like true positives that the reference method missed, meaning the CRISPR assay was slightly better at catching faint infections rather than worse. On the strip format specifically, samples with PCR cycle values around 39, which is close to the edge of what PCR can detect at all, still produced a visible line.
The group also built a separate PCR-based step to sort the virus into its two clades. That matters because Clade I and Clade II differ in how dangerous they tend to be, and knowing which one is circulating shapes the public health response. This part detected as few as 200 copies per milliliter in 40 minutes and never confused the two clades. Every clinical sample they tested turned out to be Clade II, matching what was known to be spreading in mainland China.
What the study can't say yet
The clade-typing step is the honest weak spot. It still runs on PCR, so it needs the very lab equipment the strip test was designed to skip. A clinic that can only do the field-friendly assay learns that a patient has monkeypox but not which clade, which is exactly the detail that changes the urgency. The two halves of the paper live in different worlds.
There is also the question of who was tested. Because every clinical sample carried Clade II, the strip assay's flawless record is really a record against one clade. Clade I, the more severe lineage that has driven outbreaks in Central Africa, was represented only by lab-made material, not patient samples. Whether the strip holds up on real Clade I infections, and on the messier sample types collected in the places that need this most, remains to be shown. And 202 samples, while a genuine clinical panel, is small next to the volume a national screening program handles.
Still, the direction is clear. Diagnostics that once lived inside a hospital lab keep migrating toward the point where care actually happens. A test that copies viral RNA on a warm block, lets a repurposed gene editor find the target, and prints the answer on a paper strip is the kind of tool that works where the electricity is unreliable and the nearest sequencer is a day's drive away. That is usually where an outbreak gets its head start.
Comments